Jemperli (dostarlimab)

pCPA File Number: 21991
Negotiation Status:
Under consideration for negotiation
Indication(s):
For the treatment of adult patients mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum containing regimen
Sponsor/Manufacturer:
GlaxoSmithKline Inc.
CADTH Project Number:
PC0263
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable